CD2 Immunobiology

• Published in: Frontiers in immunology 2020, Vol.11, p.1090-1090
• Main Authors: Binder, Christian, Cvetkovski, Filip, Sellberg, Felix, Berg, Stefan, Paternina Visbal, Horacio, Sachs, David H, Berglund, Erik, Berglund, David
• Format: Article
• Language: English
• Subjects: Alefacept; Animals; CD2; CD2 Antigens - immunology; CD58; costimulation; costimulation blockade; Humans; Immunological Synapses - immunology; Immunology; LFA-3 (lymphocyte functional antigen-3); Lymphocyte Activation - immunology; Medicin och hälsovetenskap; siplizumab; T cell activation; T-Lymphocytes - immunology
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2020.01090

The glycoprotein CD2 is a costimulatory receptor expressed mainly on T and NK cells that binds to LFA3, a cell surface protein expressed on e.g., antigen-presenting cells. CD2 has an important role in the formation and organization of the immunological synapse that is formed between T cells and antigen-presenting cells upon cell-cell conjugation and associated intracellular signaling. CD2 expression is upregulated on memory T cells as well as activated T cells and plays an important role in activation of memory T cells despite the coexistence of several other costimulatory pathways. Anti-CD2 monoclonal antibodies have been shown to induce immune modulatory effects and clinical studies have proven the safety and efficacy of CD2-targeting biologics. Investigators have highlighted that the lack of attention to the CD2/LFA3 costimulatory pathway is a . Overall, CD2 is an attractive target for monoclonal antibodies intended for treatment of pathologies characterized by undesired T cell activation and offers an avenue to more selectively target memory T cells while favoring immune regulation.